Hologic, Inc. (NASDAQ:HOLX) Position Boosted by Bokf Na

Bokf Na boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 6.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,508 shares of the medical equipment provider’s stock after buying an additional 631 shares during the quarter. Bokf Na’s holdings in Hologic were worth $800,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Hologic during the 4th quarter valued at approximately $27,000. Allworth Financial LP raised its holdings in shares of Hologic by 39.3% during the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares during the period. Mather Group LLC. bought a new position in shares of Hologic in the 1st quarter worth about $48,000. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 468 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.4 %

NASDAQ HOLX traded up $0.33 on Monday, reaching $78.96. The company had a trading volume of 165,287 shares, compared to its average volume of 1,604,489. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $81.00. The stock’s 50 day moving average is $74.56 and its 200-day moving average is $75.03. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52. The stock has a market cap of $18.43 billion, a price-to-earnings ratio of 39.84, a PEG ratio of 2.62 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. Hologic’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the business posted $1.06 EPS. Equities analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent research reports. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and raised their target price for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Friday, May 3rd. JPMorgan Chase & Co. lifted their price target on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Evercore ISI cut their price objective on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 2nd. Finally, Argus lifted their price target on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.